Executive with Extensive Legal Expertise in Life Sciences Strengthens Leadership Team CAMBRIDGE, Mass., July 20, 2021— Immuneering Corporation (“Immuneering”), a private biopharmaceutical company advancing a robust pipeline of oncology and…
Former Chief Financial Officer of Harvard University Strengthens Board with Financial Expertise and Considerable Board Experience CAMBRIDGE, Mass., July 14, 2021 (GLOBE NEWSWIRE) — Immuneering Corporation (“Immuneering”), a private…
Introduction: Daratumumab (DARA) is a human IgG1κ monoclonal antibody that binds with high affinity to a unique epitope on CD38. DARA monotherapy has shown promising activity in relapsed and/or refractory…
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) — Immuneering Corporation (“Immuneering”) today announced the addition of Laurie Keating to its board of directors. Ms. Keating brings more than 25 years…
Abstract Background The concurrent growth of large-scale oncology data alongside the computational methods with which to analyze and model it has created a promising environment for revolutionizing cancer diagnosis, treatment,…
Oncopanel genomic testing, which identifies important somatic variants, is increasingly common in medical practice and especially in clinical trials. Currently, there is a paucity of reliable genomic reference samples having…
Background Targeted sequencing using oncopanels requires comprehensive assessments of accuracy and detection sensitivity to ensure analytical validity. By employing reference materials characterized by the U.S. Food and Drug Administration-led SEquence…
Circulating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology, but the accuracy, sensitivity and reproducibility of ctDNA assays is poorly understood. Here we report the findings of…
CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) — Immuneering Corporation today announced the appointment of Biren Amin, M.B.A., as Chief Financial Officer. Mr. Amin comes to Immuneering from Jefferies Financial…
In this article by Gail Dutton, our co-founder and CEO Ben Zeskind discusses Immuneering’s proprietary Disease Cancelling Technology platform, and our growing pipeline of medicines targeting signaling pathways that are…
© 2021 Immuneering Corporation.
